Drug Trial Radar · NCT04022291
Comparison of Pharmacokinetic (PK) and Pharmacodynamic(PD) of Biocon Insulin 70/30 and Humulin® 70/30
Last checked: Nov 20, 2026Latest source record: Jan 30, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
78
Actual
Start
Jun 15, 2019
Primary completion
Jan 20, 2020
Study completion Jan 27, 2020
Sponsor
- Lead sponsor
- Biocon LimitedIndustry
- Sponsor type
- Industry
- Collaborators
- Profil Institut für Stoffwechselforschung GmbH
- First posted
- Jul 17, 2019
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Double (participant, investigator)
- Primary purpose
- Other
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Two-centre, randomised, double-blind, single dose, two-treatment, two-period, two sequence, crossover, 24-hour euglycaemic glucose clamp trial in healthy subjects.
Conditions
- Healthy Volunteer
Interventions
Humulin ®70/30Biological
Humulin® 70/30 is a premixed suspension of human insulin of recombinant deoxyribonucleic acid (rDNA)origin, which contains 30% short-acting human soluble insulin and 70% intermediate-acting isophane insulin. Human insulin is produced by recombinant deoxyribonucleic acid (rDNA), technology utilizing a non-pathogenic laboratory strain of Escherichia coli.
Biocon Insulin 70/30Biological
Biocon Insulin 70/30 is a premixed suspension of human insulin of recombinant deoxyribonucleic acid (rDNA)origin, which contains 30% short-acting human soluble insulin and 70% intermediate-acting isophane insulin. Biocon insulin is produced by recombinant deoxyribonucleic acid (rDNA) technology utilizing a non-pathogenic laboratory strain of Escherichia coli.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Pharmacokinetic endpoints: area under the insulin concentration curve (AUCins) 0-24hTime frame: 0-24hour
- Pharmacokinetic endpoints: insulin concentration (Cins).maxTime frame: 0-24hour
- Pharmacodynamic Endpoint: Area under curve (AUC)Glucose infusion rate (GIR).0-24hTime frame: 0-24hour
- Pharmacodynamic Endpoint: maximum glucose infusion rate (GIRmax)Time frame: 0-24hour
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Profil Mainz GmbH & Co. KG Malakoff-Passage,Rheinstraße 4C D-55116
Mainz, Germany
Profil Institut für Stoffwechselforschung GmbH Hellersbergstr. 9 D-41460 Neuss
Neuss, Germany
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.